Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

NCT01324245
View directory record Official record
Conditions
Salt-sensitive Hypertension
Interventions
Fenoldopam
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Dietary Salt on Post-exercise Hypotension

NCT03565653
View directory record Official record
Conditions
Blood Pressure, Post-Exercise Hypotension
Interventions
High dietary salt, Placebo
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT03132532
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Study of EB-001 in Facial Scar Reduction

NCT03346902
View directory record Official record
Conditions
Mohs Surgery
Interventions
EB-001, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Bonti, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Biology and Experience of Eating in Women With Obesity

NCT02805972
View directory record Official record
Conditions
Obesity
Interventions
Naloxone, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®

NCT02514772
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2013 - A Proposed biosimilar rituximab, Originator rituximab - Rituxan ® or MabThera ®
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
39
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 20, 2026, 9:06 AM EDT
Recruiting Phase 2Phase 3 Interventional

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

NCT06947928
View directory record Official record
Conditions
Advanced Or Metastatic Merkel Cell Carcinoma
Interventions
IFx-Hu2.0, Placebo, Pembrolizumab
Drug
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 9:06 AM EDT
Terminated Phase 1 Interventional

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

NCT03069911
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
OnabotulinumtoxinA, Control
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 20, 2026, 9:06 AM EDT
Not listed Not applicable Interventional

"Platelet Rich Plasma for the Management of Post-Viral Olfactory Dysfunction.

NCT05666492
View directory record Official record
Conditions
Olfactory Disorder, Olfaction Disorders
Interventions
Platelet rich plasma, Saline
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

NCT05468736
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
6 Months to 11 Years
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
47
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vascular Effects of Dietary Salt in Humans With Salt-Resistant Blood Pressure

NCT03424993
View directory record Official record
Conditions
Healthy
Interventions
Dietary Sodium Restriction, Control
Other
Lead sponsor
University of Delaware
Other
Eligibility
21 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 20, 2026, 9:06 AM EDT
Terminated Phase 4 Interventional Results available

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

NCT01260649
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ketamine, IV Saline, ECT, Muscle Relaxant, Anesthetic Agents
Drug · Other · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 20, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 20, 2026, 9:06 AM EDT
Not listed Phase 2 Interventional

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

NCT05223816
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Interventions
VG161, Nivolumab Injection [Opdivo]
Drug
Lead sponsor
Virogin Biotech Canada Ltd
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 20, 2026, 9:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Acute Salt Handling in Orthostatic Intolerance

NCT00581633
View directory record Official record
Conditions
Postural Tachycardia Syndrome, Orthostatic Tachycardia, Orthostatic Intolerance
Interventions
normal saline (0.9%)
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 9:06 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

INB03 for the Treatment of Pulmonary Complications From COVID-19

NCT04370236
View directory record Official record
Conditions
COVID-19
Interventions
INB03, Placebo
Drug
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis

NCT03391414
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hypertonic bicarbonate, sodium chloride
Drug
Lead sponsor
Joseph Pilewski
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 20, 2026, 9:06 AM EDT
Active, not recruiting Phase 3 Interventional

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 9:06 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study

NCT06094816
View directory record Official record
Conditions
Salt-Sensitivity of Blood Pressure
Interventions
Furosemide (Diuretic), Hypertonic Saline Infusion
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
40 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620
View directory record Official record
Conditions
Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study

NCT05455086
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Cigarette Smoking, Computed Tomography, Positron Emission Tomography, Questionnaire Administration
Behavioral · Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions

NCT02041273
View directory record Official record
Conditions
Healthy
Interventions
palbociclib isethionate (phase 1 and 2 studies), palbociclib commercial free base capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 20, 2026, 9:06 AM EDT
Recruiting Phase 2 Interventional

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

NCT02734537
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
Drug · Radiation · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
679
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 450 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Results available

Clinical and Microbiologic Outcomes of aPDT in the Non-surgical Treatment of Implant Inflammation

NCT04187053
View directory record Official record
Conditions
DENT IMPLANTS, LASER
Interventions
Conventional mechanical therapy, Saline, Methylene Blue, Light emitting laser, Non-light emitting laser
Procedure · Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 20, 2026, 9:06 AM EDT